Pilot trial to prevent type I diabetes: Progression to overt IDDM despite oral nicotinamide
Authors:
- R.A. JacksonRJR.A. Jackson
- J.S. SoeldnerJSJ.S. Soeldner
- G.S. EisenbarthGEG.S. Eisenbarth
- 1 October 1989
- journal article
- research article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 2 (5) , 733-737
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- NICOTINAMIDE MAY EXTEND REMISSION PHASE ININSULIN-DEPENDENT DIABETESThe Lancet, 1987
- Type I Diabetes MellitusNew England Journal of Medicine, 1986
- Effect of Poly(ADP-ribose) Synthetase Inhibitor Administration to Rats Before and After Injection of Alloxan and Streptozotocin on Islet Proinsulin SynthesisDiabetes, 1983
- Preventive and Therapeutic Effects of Large-Dose Nicotinamide Injections on Diabetes Associated with Insulitis: An Observation in Nonobese Diabetic (NOD) MiceDiabetes, 1982
- Reactions to niacinamideJournal of the American Academy of Dermatology, 1981
- Protection by picolinamide, a novel inhibitor of poly (ADP-ribose) synthetase, against both streptozotocin-induced depression of proinsulin synthesis and reduction of NAD content in pancreatic isletsBiochemical and Biophysical Research Communications, 1980
- Nicotinamide: Suppression of Lymphocyte Transformation with a Component Identified in Human Transfer FactorThe Journal of Immunology, 1976
- Hepatic Toxicity from Large Doses of Vitamin B3(Nicotinamide)New England Journal of Medicine, 1973
- Megavitamin B-3 Therapy for SchizophreniaCanadian Psychiatric Association Journal, 1971
- An Evaluation of Niacinamide in the Treatment of Childhood SchizophreniaAmerican Journal of Psychiatry, 1970